|Table of Contents|

A retrospective study of 155 cases primary small carcinoma of esophagus prognosis analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 19
Page:
3700-3704
Research Field:
Publishing date:

Info

Title:
A retrospective study of 155 cases primary small carcinoma of esophagus prognosis analysis
Author(s):
CAO Heng; LEI Ruixue; CHEN Jing; XU Lin; CUI Donghai; HOU Yongjie; SU Wenzhong; ZHANG Yaowen
Anyang Tumor Hospital (Anyang Cancer Hospital Affiliated to Henan University of Science and Technology),Henan Anyang 455000,China.
Keywords:
esophageal; primary small carcinoma of esophagus; prognosis analysis
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2024.19.013
Abstract:
Objective:To analyze the clinicopathological characteristics and treatment patterns of patients with primary small carcinoma of esophagus（PSCCE） to explore the factors affecting the prognosis of patients,hoping to provide a reference for the clinical treatment and prognosis evaluation of the disease.Methods:A retrospective analysis was performed on patients with PSCCE who were admitted to our hospital from January 2006 to June 2020.Patient data included age,gender,underlying disease,family history of cancer,smoking history,drinking history,depth of primary invasion,location,lymph node metastasis,distant metastasis,whether liver metastasis was combined,whether there was neurological invasion or vascular cancer thrombus in postoperative pathology,treatment mode,and follow-up.Kaplan-Meier survival curve was used to analyze overall survival (OS) of patients,Log-rank was used for univariate analysis,and COX proportional risk regression model was used for multi-factor analysis to explore independent prognostic factors affecting survival of patients with PSCCE.The optimal treatment mode was selected by subgroup analysis.Results:The median age of onset of PSCCE in 155 patients included in this study was 65.8 years,and the ratio of males to females was 1.18∶1.00.The median survival time was 15 months,and the 1-year and 3-year survival rates were 63.2% and 13.5%,respectively.Univariate analysis showed that the factors influencing OS included age,positive presence of vascular embolic/nerve invasion,depth of esophageal invasion at first diagnosis,lymph node metastasis at first diagnosis,distant metastasis at first diagnosis,treatment mode,and presence of liver metastasis.The results of multivariate analysis showed that the independent risk factors for OS were lymph node metastasis (HR=2.492,95%CI:1.579~3.933,P＜0.001) and liver metastasis (HR=1.978,95%CI:1.230~3.448,P=0.005).The protective factors were T1 (T1 vs T3-4,HR=0.541,95%CI:0.301~0.976,P=0.041) and combined treatment mode (P＜0.001).Conclusion:The retrospective study shows that early diagnosis and combined treatment may improve the prognosis of PSCCE patients,and the prognosis of PSCCE patients with lymph node metastasis and liver metastasis is poor.

References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］CHEN W,ZHENG R,BEADEP D,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］DING J,JI J,PAN P,et al.A retrospective study of different treatments of limited-stage small-cellesophageal carcinoma and associated prognostic factor analysis［J］.Dis Esophagus,2013,26(7):696-702.
［4］XU XJ,YANG Y,CAO LM,et al.Lymph node metastasis and recurrence in primarysmall cell carcinoma of the esophagus:A retrospective study of 125 cases［J］.Cancer Biother Radiopharm,2019,34(7):459-463.
［5］MCKEOWN F.Oat-cell carcinoma of the oesophagus［J］.J Pathol Bacteriol,1952,64(4):889-891.
［6］HIROTAKA ISHIDA,ATSUKO KASAJIMA,TAKASHI KAMEIL,et al.SOX2 and Rb1 in esophageal small-cell carcinoma:their possible involvement in pathogenesis［J］.Mod Pathol,2017,30(5):660-671.
［7］GAN JF,ZHANG YL,KE XR,et al.Dysregulation of pAK1 is associated with DNA damage and is of prognostic importance in primary esophageal small cell carcinoma［J］.Int J Mol Sci,2015,16(6):12035-12050.
［8］DU WU,PANG QS,WANG P.Progress in investigation of molecular mechanisms and treatment of primary small cell carcinoma of the esophagus［J］.Chinese Journal of Clinical Oncology，2021,48(14):738-742.
［9］ANDREW TWONG,MENG SHAO,JUSTIN RINEER,et al.Treatment and survival outcomes of small cell carcinoma of the esophagus:ananalysis of the national cancer data base［J］.Dis Esophagus,2017,30(2):1-5.
［10］VIVEK VERMA,RICHARD LSLEIGHTHOLM,PENNY FANG,et al.National cancer database report of nonmetastatic esophagealsmall cell carcinoma［J］.Cancer Med,2018,7(12):6365-6373.
［11］SU HX,LIU D,CHEN YZ,et al.Systematic review on treatment and prognosis of small cell esophageal carcinoma［J］.Modern Oncology,2014,22(8):1824-1830.
［12］CAO H,SONG XK,HONG YG.Prognosis analysis of 148 patients with limited-stage small cell lung cancer［J］.Chinese Journal of Cancer Prevention,2018,25(23):1649-1653.
［13］MANSFIELD AS,KAZARNOWICZ A,KARASEVA N,et al.Safety and patient-reported outcomes of atezolizumab,carboplatin,and etoposide in extensive-stage small-cell lung cancer (IMpower133):a randomized phase Ⅰ/Ⅲ trial［J］.Ann Oncol,2020,31(2):310-317.
［14］LUISPAZ-AIES,MIKHAIL DVORKIN,YUANBIN CHEN,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASpIAN):a randomised,controlled,open-label,phase 3 trial［J］.Lancet,2019,394(10212):1929-1939.
［15］CHENG Y,HAN L,WU L,et al.Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer:The ASTRUM-005 randomized clinical trial［J］.JAMA,2022,328（12）:1223-1232.
［16］WANG J,ZHOU CC,YAO WX,et al.Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CApSTONE-1):a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2022,23(6):739-747.

Memo

Memo:
河南省科技攻关项目（编号：242102310150,212102310702）
Last Update: 2024-08-30